CaSR could be targeted through NPS2143, a calcilytic drug with a good specificity and minor side effects [34], that has been shown to inhibit in vitro both proliferation and migration of the PCa cell line PC3 [35]. This evidence concerns the gene CASR and posterior cortical atrophy.